PCN110 Cost-Utility Analysis of Adjuvant Trastuzumab Emtansine Versus Trastuzumab in Patients with HER2+ EARLY Breast Cancer with Residual Invasive Disease after Neoadjuvant Therapy in Spain
Autor: | I. Arroyo, R. Colomer, J. Costa-Samarra, T. Gallego |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
Cost–utility analysis medicine.medical_specialty Invasive disease business.industry Health Policy medicine.medical_treatment Public Health Environmental and Occupational Health chemistry.chemical_compound chemistry Trastuzumab emtansine Trastuzumab Internal medicine medicine In patient business Adjuvant Neoadjuvant therapy Early breast cancer medicine.drug |
Zdroj: | Value in Health. 23:S442 |
ISSN: | 1098-3015 |
Databáze: | OpenAIRE |
Externí odkaz: |